In addition, other report has demonstrated that the dual PI3KCI/mTOR inhibitor PI-103 and the Mdm2 inhibitor Nutlin-3 is a combination strategy aimed at inhibiting PI3KCI/Akt/mTOR signaling and activating p53 signaling in AML [31]. Here, MDM2 is linked to acute myeloid leukemia.